Afya (NASDAQ:AFYA) VP Sells $215,740.00 in Stock

Key Points

• Afya VP De Sousa Anibal Jose Grifo sold 14,000 shares on April 13 at an average price of $15.41 for $215,740, trimming his position by 31.11% to 31,000 shares (≈$477,710); he also sold 5,000 shares on April 7 at $15.20.
• Shares fell about 1.3% to $15.46 amid mixed results—Q1 EPS of $0.41 beat estimates ($0.36) but revenue of $147.08M missed expectations ($174.74M); the company has a $1.45B market cap and an average analyst rating of "Hold" with a $17.30 target.

Afya Limited (NASDAQ:AFYA - Get Free Report) VP De Sousa Anibal Jose Grifo sold 14,000 shares of the stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $15.41, for a total value of $215,740.00. Following the completion of the sale, the vice president owned 31,000 shares of the company's stock, valued at approximately $477,710. This trade represents a 31.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

De Sousa Anibal Jose Grifo also recently made the following trade(s):

• On Tuesday, April 7th, De Sousa Anibal Jose Grifo sold 5,000 shares of Afya stock. The shares were sold at an average price of $15.20, for a total value of $76,000.00.

Afya Stock Down 1.3%

Shares of AFYA stock traded down $0.20 during trading hours on Tuesday, reaching $15.46. The company had a trading volume of 64,289 shares, compared to its average volume of 117,213. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.20 and a current ratio of 2.20. Afya Limited has a twelve month low of $13.00 and a twelve month high of $19.90. The company has a market capitalization of $1.45 billion, a P/E ratio of 10.59, a price-to-earnings-growth ratio of 0.67 and a beta of 0.48. The stock's fifty day simple moving average is $14.49 and its 200 day simple moving average is $14.67.

Afya (NASDAQ:AFYA - Get Free Report) last posted its earnings results on Wednesday, March 11th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.36 by $0.05. Afya had a return on equity of 18.77% and a net margin of 20.31%.The business had revenue of $147.08 million during the quarter, compared to analyst estimates of $174.74 million. As a group, sell-side analysts expect that Afya Limited will post 1.52 earnings per share for the current fiscal year.

Afya Dividend Announcement

The firm also recently declared an annual dividend, which was paid on Monday, April 6th. Investors of record on Wednesday, March 25th were issued a $0.656 dividend. The ex-dividend date of this dividend was Wednesday, March 25th. This represents a yield of 433.0%. Afya's dividend payout ratio is currently 44.52%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Van ECK Associates Corp lifted its holdings in Afya by 15.7% during the 3rd quarter. Van ECK Associates Corp now owns 10,170 shares of the company's stock worth $159,000 after buying an additional 1,377 shares during the last quarter. Daiwa Securities Group Inc. bought a new position in Afya during the 4th quarter worth approximately $43,000. Arrowstreet Capital Limited Partnership lifted its holdings in Afya by 5.6% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 68,169 shares of the company's stock worth $1,217,000 after buying an additional 3,626 shares during the last quarter. Militia Capital Partners LP bought a new position in Afya during the 2nd quarter worth approximately $71,000. Finally, Fairtree Asset Management Pty Ltd lifted its holdings in Afya by 22.3% during the 4th quarter. Fairtree Asset Management Pty Ltd now owns 30,697 shares of the company's stock worth $473,000 after buying an additional 5,599 shares during the last quarter. Institutional investors own 88.02% of the company's stock.

Analyst Ratings Changes

AFYA has been the subject of a number of analyst reports. Zacks Research raised Afya from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 7th. Weiss Ratings reissued a "hold (c)" rating on shares of Afya in a report on Wednesday, January 21st. Wall Street Zen raised Afya from a "buy" rating to a "strong-buy" rating in a report on Saturday, March 14th. UBS Group reissued a "neutral" rating and issued a $16.00 price target (down from $18.00) on shares of Afya in a report on Friday, January 16th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and issued a $22.00 price target (down from $24.50) on shares of Afya in a report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $17.30.

Afya Company Profile

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya's offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.